{"entity":{"id":"peter-thuss-patience","kind":"person","name":"Peter Thuss-Patience","aka":[],"tldr":"Berlin oncologist who led GATSBY, the trial showing that the antibody-drug conjugate T-DM1 did not beat taxane chemotherapy in previously treated HER2-positive stomach cancer.","summary":"Peter Thuss-Patience is a gastrointestinal oncologist at Charité in Berlin. He led the German AIO trial that established second-line irinotecan over best supportive care in gastric cancer, and was first author of the 2017 Lancet Oncology report of GATSBY, in which trastuzumab emtansine failed to improve survival over taxane chemotherapy in HER2-positive advanced gastric cancer after first-line treatment.","asOf":"2026-09-18","links":[],"tags":["gastric","trialist"],"related":[],"cancers":["gastric-her2-positive","gastric"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["charite"],"pathways":[],"terms":[],"trials":["gatsby"],"people":[],"bottlenecks":[],"keyPapers":["paper-flot4-lancet-2019","paper-peter-thuss-patience-eur-j-cancer-2011","paper-peter-thuss-patience-ann-oncol-2019"],"journals":[],"dependsOn":[],"notes":[],"role":"Medical oncologist, Charité Universitätsmedizin Berlin","institutionId":"charite","specialisms":["Gastric and oesophageal cancer","Second-line chemotherapy","Antibody-drug conjugates"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Thuss-Patience%5BAuthor%5D"}],"papers":[{"title":"FLOT4-AIO: perioperative FLOT versus ECF/ECX for resectable gastric or gastro-oesophageal junction adenocarcinoma","journal":"The Lancet","year":2019,"url":"https://doi.org/10.1016/S0140-6736(18)32557-1","doi":"10.1016/S0140-6736(18)32557-1","note":"Europe PMC author record matched by affiliation (Charité Universitätsmedizin Berlin); 2016 citations on Europe PMC."},{"title":"Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer--a randomised phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO)","journal":"European Journal of Cancer","year":2011,"url":"https://doi.org/10.1016/j.ejca.2011.06.002","doi":"10.1016/j.ejca.2011.06.002","note":"Europe PMC author record matched by affiliation (Charité Universitätsmedizin Berlin); 448 citations on Europe PMC."},{"title":"A multicentre, phase IIa study of zolbetuximab as a single agent in patients with recurrent or refractory advanced adenocarcinoma of the stomach or lower oesophagus: the MONO study","journal":"Annals of Oncology","year":2019,"url":"https://doi.org/10.1093/annonc/mdz199","doi":"10.1093/annonc/mdz199","note":"Europe PMC author record matched by affiliation (Charité Universitätsmedizin Berlin); 204 citations on Europe PMC."}]},"route":"/people/peter-thuss-patience/","neighbours":{"cancer":[{"id":"gastric","kind":"cancer","name":"Gastric & gastro-oesophageal junction cancer","route":"/cancers/gastric/"},{"id":"gastric-her2-positive","kind":"cancer","name":"HER2-positive gastric cancer","route":"/cancers/gastric-her2-positive/"}],"institution":[{"id":"charite","kind":"institution","name":"Charité Universitätsmedizin Berlin","route":"/institutions/charite/"}],"trial":[{"id":"gatsby","kind":"trial","name":"GATSBY","route":"/trials/gatsby/"}],"paper":[{"id":"paper-peter-thuss-patience-ann-oncol-2019","kind":"paper","name":"A multicentre, phase IIa study of zolbetuximab as a single agent in patients with recurrent or refractory advanced adenocarcinoma of the stomach or lower oesophagus: the MONO study","route":"/key-papers/paper-peter-thuss-patience-ann-oncol-2019/"},{"id":"paper-flot4-lancet-2019","kind":"paper","name":"FLOT4-AIO: perioperative FLOT versus ECF/ECX for resectable gastric or gastro-oesophageal junction adenocarcinoma","route":"/key-papers/paper-flot4-lancet-2019/"},{"id":"paper-peter-thuss-patience-eur-j-cancer-2011","kind":"paper","name":"Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer--a randomised phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO)","route":"/key-papers/paper-peter-thuss-patience-eur-j-cancer-2011/"}]}}